Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (16187)	2/14/2003 3:25:37 PM
From: Cacaito	Read Replies (3) \| Respond to of 17367

Believe in Raptiva Lfa-1 actions? Important date June 18-22: ..."LFA-1 (IC747). Results from a Phase II study of this compound in psoriasis is expected to be released at the International Psoriasis Society (IPS) meeting in New York in mid June (June 18-22)."... Raptiva proved that acting at the LFA-1 receptor improves lesions in psoriasis affected patients. IC747 (Ic = Icos, 747 = something like the jumbo from Boeing from Seattle the base of Icos) is the ORAL "version" of Raptiva. IC747 is a joint venture of Icos and Biogen. If it works as Raptiva (I am bias and definitely expect IC747 to be BETTER than Raptiva) it will take the whole psoriasis market in the future. A phase IIb (III if pIIa is a success) will start in the H2 of 2003, end by 2004, in the market by 2005 (2006 if late) just when Raptiva will be entering market IC747 will follow by. There is nothing to lift xoma value till June 18, but if June 18 comes and the JUMBO IC747 comes with good results it will not help xoma shares prices, and Baxter will keep helping !!! I do not expect the mlnmxoma pipeline to succeed, but it could surprise and save xoma from missery, but I strongly doubt it.